Vertex Pharmaceuticals Incorporated Stock
Equities
VRTX
US92532F1003
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
397.5 USD | -0.06% | +0.81% | -2.31% |
Financials (USD)
Sales 2024 * | 10.72B | Sales 2025 * | 11.74B | Capitalization | 103B |
---|---|---|---|---|---|
Net income 2024 * | 3.86B | Net income 2025 * | 4.44B | EV / Sales 2024 * | 8.01 x |
Net cash position 2024 * | 16.91B | Net cash position 2025 * | 21.28B | EV / Sales 2025 * | 6.94 x |
P/E ratio 2024 * |
26.7
x | P/E ratio 2025 * |
23.2
x | Employees | 5,400 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.89% |
Latest transcript on Vertex Pharmaceuticals Incorporated
1 day | -0.06% | ||
1 week | -0.61% | ||
Current month | -4.91% | ||
1 month | -4.75% | ||
3 months | -8.80% | ||
6 months | +11.88% | ||
Current year | -2.31% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 51 | 17-01-31 | |
Jeffrey Leiden
CHM | Chairman | 68 | 09-07-07 |
Charles Wagner
DFI | Director of Finance/CFO | 55 | 19-04-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 17-06-07 |
Jeffrey Leiden
CHM | Chairman | 68 | 09-07-07 |
Bruce Sachs
BRD | Director/Board Member | 64 | 97-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.67% | 0 M€ | 0.00% | - | |
7.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 397.5 | -0.06% | 682,467 |
24-04-25 | 397.7 | -0.76% | 787,700 |
24-04-24 | 400.8 | -1.02% | 806,473 |
24-04-23 | 404.9 | +1.25% | 1,070,343 |
24-04-22 | 399.9 | +1.43% | 1,393,886 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B | |
-24.71% | 8.08B |
- Stock Market
- Equities
- VRTX Stock